Series A financing led by two leading global venture capital firms – Sequoia Capital China and Highlight Capital SAN DIEGO, April 10, 2019-- Cullgen Inc. (Cullgen), a biotechnology company dedicated to the development of targeted protein degraders for the treatment of diseases lacking effective therapeutic approaches, today announced it has received a $16 million Series A financing from two prominent international venture capital firms, Sequoia Capital China (Sequoia) and Highlight Capital (HC).